Examination of efficacy and safety treated by Mirogabalin in patients with peripheral neuropathy in Orthopaedic disease

Examination of efficacy and safety treated by Mirogabalin in patients with peripheral neuropathy in Orthopaedic disease - Examination of efficacy and safety treated by Mirogabalin in patients with peripheral neuropathy in Orthopaedic disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000037150

Enrollment

Registered

2019-06-25

Start date

2019-06-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with peripheral neuropathy in Orthopaedic diseases

Interventions

Mirogabalin group Pregabalin group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 More than 40mm of VAS or 40 points of NRS in patients with peripheral neuropathy 2 Patients who agree with this study

Exclusion criteria

Exclusion criteria: 1 Patients who have taken Mirogabalin or Prerogabalin before 2 Patients who are allergic to Mirogabalin or Prerogabalin 3 Others

Design outcomes

Primary

Measure	Time frame
Percent changes from the baseline values prior to treatment	—

Countries

Japan

Contacts

Public ContactYukio Nakamura

Shinshu University School of Medicine Dept. of Orthopaedic Surgery

yxn14@aol.jp0263372659

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026